Sogari P R, Telöken C, Souto C A
Department of Urology, Santa Casa de Porto Alegre, Brazil.
J Urol. 1997 Nov;158(5):1760-3. doi: 10.1016/s0022-5347(01)64122-3.
We determined the efficacy of atropine sulfate combined with papaverine hydrochloride, prostaglandin E1 and phentolamine mesylate in the pharmacological erection test.
A total of 230 consecutive patients with erectile dysfunction was randomized for pharmacological erection test and received an intracorporeal combination of 50 mg. papaverine hydrochloride, 10 micrograms. prostaglandin E1, 0.2 mg. phentolamine mesylate and 0.075 mg. of atropine sulfate (group 1), or the same combination without atropine sulfate (group 2). Erectile response was evaluated subjectively and by intracorporeal pressure measurement.
In group 1, 40 patients (35.1%) showed only tumescence, and 22 (19.3%) had poor erection. In group 2, 45 patients (39.5%) had tumescence and 17 (14.9%) poor erection. In both groups 52 patients (45.6%) had rigid erection. There was no statistically significant difference regarding erectile response and intracorporeal pressure.
The addition of atropine sulfate did not improve results of the pharmacological erection test when combined with 50 mg. papverine hydrochloride, 10 micrograms, prostaglandin E1, and 0.2 mg. phentolamine mesylate.
我们确定了硫酸阿托品联合盐酸罂粟碱、前列腺素E1和甲磺酸酚妥拉明在药理勃起试验中的疗效。
总共230例连续的勃起功能障碍患者被随机分配进行药理勃起试验，并接受了50毫克盐酸罂粟碱、10微克前列腺素E1、0.2毫克甲磺酸酚妥拉明和0.075毫克硫酸阿托品的体内联合用药（第1组），或不含硫酸阿托品的相同联合用药（第2组）。通过主观评估和体内压力测量来评估勃起反应。
在第1组中，40例患者（35.1%）仅出现肿胀，22例（19.3%）勃起不佳。在第2组中，45例患者（39.5%）出现肿胀，17例（14.9%）勃起不佳。两组中均有52例患者（45.6%）出现坚挺勃起。在勃起反应和体内压力方面没有统计学上的显著差异。
当与50毫克盐酸罂粟碱、10微克前列腺素E1和0.2毫克甲磺酸酚妥拉明联合使用时，添加硫酸阿托品并未改善药理勃起试验的结果。
